Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis and Bristol Myers Squibb halt multiple CAR-T clinical trials for autoimmune diseases following patient deaths and safety reviews.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent coverage from outlets including Reuters, Bloomberg, the Wall Street Journal, Barron's, BioSpace, BioPharma Dive, Fierce Biotech, Endpoints News, FirstWord Pharma, and GuruFocus details a major development in clinical research. Novartis has halted eight CAR-T clinical trials spanning immunology, neurology, and autoimmune diseases. This decision follows three patient deaths occurring within these studies. In tandem with the Novartis announcement, Bristol Myers Squibb has also paused its own CAR-T programs for lupus and other autoimmune conditions due to safety events and concerns. Reporting heavily emphasizes the scope of the clinical holds, which impact multiple active research pipelines focusing on severe autoimmune disorders.
Specialized life sciences publications like BioSpace, BioPharma Dive, Fierce Biotech, and Endpoints News tracked the unfolding sequence closely, noting that Bristol Myers Squibb followed the initial Novartis halt by pausing its related studies as well. General financial and business coverage from Bloomberg, Barron's, and the Wall Street Journal examined the broader market and corporate implications of these safety reviews, while outlets like GuruFocus and finance.biggo.com evaluated the financial positioning and stock movements of the companies involved. The context provided by the coverage centers on the experimental application of chimeric antigen receptor T-cell therapies outside of oncology, specifically targeting complex autoimmune and neurological conditions such as lupus. These trials represent a major frontier in drug development, shifting advanced cell therapies from cancer treatment into chronic immune-mediated diseases. However, the emergence of fatal safety events highlights the substantial clinical risks inherent in these investigative protocols, prompting immediate regulatory and corporate caution across major pharmaceutical developers.
Future developments will depend on the findings of the ongoing safety reviews initiated by the sponsoring companies. Coverage does not yet specify when the trials might resume or what specific adverse events triggered the safety reviews beyond the reported deaths. Observers are monitoring whether additional pharmaceutical firms with similar pipelines will implement precautionary pauses, and how regulatory authorities will respond to the safety data emerging from the halted studies.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 75d ago.
Quick answers
Which companies have paused their CAR-T trials?
Novartis and Bristol Myers Squibb have paused their CAR-T clinical trials.
What prompted the trial halts?
Coverage attributes the halts to three patient deaths and broader safety events and concerns.
Which disease areas are affected by these trial pauses?
The affected studies target lupus, autoimmune diseases, immunology, and neurology indications.
Coverage (12)
- Novartis Halts Eight CAR-T Trials After Three Patient Deaths finance.biggo.com · 78d ago
- Novartis, Bristol Myers Squibb pause CAR-T trials for lupus and other autoimmune diseases for safety reviews Lupus Foundation of America · 78d ago
- Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events BioSpace · 78d ago
- Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths Barron's · 78d ago
- Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports Reuters · 78d ago
- Novartis Pauses Autoimmune Drug Trials After Three Patients Die Bloomberg.com · 78d ago
- NVS Looks 16.5% Overvalued on GF Value™ Amid Dividend Safety Foc GuruFocus · 78d ago
- Novartis pauses immunology, neuro CAR-T studies after three patient deaths FirstWord Pharma · 78d ago
- Novartis Pauses Autoimmune Cell Therapy Studies After Deaths WSJ · 78d ago
- Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns BioPharma Dive · 78d ago
- UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies Fierce Biotech · 78d ago
- Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused Endpoints News · 78d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Trying Tourette's device was the best day of my life
Clinical trials show a new £500 wrist-worn nerve-stimulation device cuts Tourette's tics by over 25 percent.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.